1 published article · Updated continuously
14 trials tracked for Leiomyoma: 7 in phase 3 or 4 and 3 with published results. The most-cited published study has 1566 citations.
Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Ulipristal acetate (UPA) is effective for controlling bleeding in women with uterine fibroids. In two phase 3 trials, UPA 5 mg and 10 mg led to absence of bleeding during the last 35 consecutive days of treatment in 42.0% and 54.8% of participants, respectively, compared to 0% with placebo in treatment course 1 5. Similar results were observed in another phase 3 trial, with 47.2% and 58.3% achieving amenorrhea versus 1.8% for placebo 4. UPA also improved quality of life, as measured by the UFS-QOL revised activities subscale, with changes from baseline ranging from 18.26 to 61.04 across doses and studies 4.
Uterine fibroid embolization (UFE) improved symptom-specific quality of life, with UFS-QOL scores of 18.0 and 22.9 reported in a phase 4 trial 3. Standard care was evaluated in a phase 4 trial 1. Letrozole did not significantly change fibroid-related symptoms (p=0.24) in a small phase 4 study 2. Dexamethasone was associated with pain scores ranging from 0.8 to 6.3 on the VAS in a phase 3 trial 6. Mifepristone was studied in a phase 3 trial 7.
AI synthesis of 14 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
